imatinib mesylate has been researched along with Minimal Disease, Residual in 156 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 87 (55.77) | 29.6817 |
| 2010's | 65 (41.67) | 24.3611 |
| 2020's | 4 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Andrade, A; Bass, F; Benavente, R; Cabrera, ME; Cid, F; Encina, A; Molina, J; Monardes, V; Puga, B | 1 |
| Benesova, A; Cerveira, N; Colomer, D; Coriu, D; Cross, NCP; Ernst, T; Franke, GN; Glauche, I; Gottardi, E; Gottschalk, A; Hochhaus, A; Hovorkova, L; Izzo, B; Jurcek, T; Klamova, H; Koblihova, J; Lion, T; Markova, MS; Mayer, J; Motlova, E; Polakova, KM; Polivkova, V; Roeder, I; Salmon, M; Schäfer, V; Srbova, D; Venturi, C; Vigneri, P; White, HE; Zackova, D; Zawada, M; Zizkova, H; Zuna, J | 1 |
| Biondi, A; Borowitz, MJ; Cario, G; Carroll, AJ; Cazzaniga, G; Devidas, M; Gastier-Foster, JM; Heerema, NA; Hunger, SP; Loh, ML; Martin-Regueira, P; Moorman, AV; Raetz, EA; Reshmi, SC; Saha, V; Schrappe, M; Schultz, KR; Silverman, LB; Slayton, WB; Tran, TH; Valsecchi, MG | 1 |
| Akahoshi, Y; Atsuta, Y; Fukuda, T; Ichinohe, T; Kako, S; Kanda, Y; Mizuta, S; Nakamae, H; Nishiwaki, S; Ohashi, K; Onizuka, M; Ozawa, Y; Shiratori, S; Takahashi, S; Tanaka, M; Uchida, N | 1 |
| Altamura, H; Braley, J; Branford, S; Carne, L; Dang, P; Grose, R; Hughes, TP; Kok, CH; McLean, J; Pagani, IS; Ross, DM; Rwodzi, Z; Saunders, VA; Shanmuganathan, N; Watts, S; White, DL; Yeung, DT; Yong, ASM | 1 |
| Azam, M; Bouso, MF; Cancelas, JA; Gomaa, A; Grimes, HL; Huber, E; Kesarwani, M; Kincaid, Z; Komurov, K; Latif, T; Mulloy, JC; Rohrabaugh, S; Siddiqui, Z; Xu, M | 1 |
| Bertucci, F; Blay, JY; Bompas, E; Bonvalot, S; Bouché, O; Delhorme, JB; Duffaud, F; Gagniere, J; Isambert, N; Meeus, P; Salas, S; Stoeckle, E; Toulmonde, M | 1 |
| Cai, H; Duan, MH; Li, H | 1 |
| Alten, J; Aricò, M; Biondi, A; Bleckmann, K; Castor, A; Cavé, H; Cazzaniga, G; Conter, V; De Lorenzo, P; Escherich, G; Ferrari, GM; Gandemer, V; Hancock, J; Köhler, R; Leoni, V; Madsen, HO; Pieters, R; Röttgers, S; Saha, V; Schrappe, M; Stadt, UZ; Stary, J; Valsecchi, MG; van der Velden, V; Zuna, J | 1 |
| Gaynon, PS | 1 |
| Braley, J; Branford, S; Dang, P; Goyne, JM; Hughes, TP; Kommers, IO; Nicola, M; Pagani, IS; Ross, DM; Saunders, VA; White, DL; Yeung, DT | 1 |
| Azad, NA; Jeelani, S; Pandith, AA; Rasool, R; Shah, ZA | 1 |
| Ai, T; Horii, T; Kawaguchi, A; Kimura, S; Kitamura, H; Misawa, S; Ohsaka, A; Tabe, Y; Tsuchiya, K; Yuri, M | 1 |
| Radich, J | 1 |
| Albert, C; Goerlitz, K; Krumbholz, M; Lawlor, J; Metzler, M; Suttorp, M | 1 |
| Berger, MG; Boureau, L; Cayssials, E; Charbonnier, A; Coiteux, V; Cony-Makhoul, P; Dubruille, V; Dulucq, S; Escoffre-Barbe, M; Etienne, G; Gardembas, M; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Henni, T; Ianotto, JC; Jardel, H; Johnson-Ansah, H; Joly, B; Larosa, F; Legros, L; Lenain, P; Liu, J; Mahon, FX; Martiniuc, J; Nicolini, FE; Rea, D; Rigal-Huguet, F; Rousselot, P; Turlure, P; Varet, B; Villemagne, B; Zunic, P | 1 |
| Arthur, C; Branford, S; Dang, P; Filshie, RJ; Goyne, JM; Grigg, AP; Hughes, TP; Melo, JV; Mills, AK; Ross, DM; Schwarer, AP; Seymour, JF; Slader, C; White, DL; Yeung, DT | 1 |
| Burger, JA; Challagundla, P; Champlin, RE; Cortes, JE; Estrov, Z; Faderl, S; Ferrajoli, A; Garris, R; Huang, X; Jorgensen, JL; Kantarjian, HM; Kebriaei, P; Luthra, R; O'Brien, S; Ravandi, F; Thomas, DA; Wang, SA; Wen, S | 1 |
| Bilban, M; Einwallner, E; Herndlhofer, S; Hoermann, G; Jaeger, E; Mitterbauer-Hohendanner, G; Pernicka, E; Schwarzinger, I; Sillaber, C; Simonitsch-Klupp, I; Steiner, I; Valent, P | 1 |
| Bhojwani, D; Campana, D; Cheng, C; Choi, JK; Coustan-Smith, E; Howard, SC; Inaba, H; Jacobsen, J; Jeha, S; Metzger, ML; Pei, D; Pui, CH; Raimondi, S; Ribeiro, RC; Rubnitz, JE; Sandlund, JT; Shurtleff, SA | 1 |
| Cao, H; Du, CY; He, YL; Jie, ZG; Liang, XB; Shi, YQ; Song, C; Wang, YP; Yan, ZS; Zhou, Y | 1 |
| Katagiri, S; Ohyashiki, K; Okabe, S; Tanaka, Y; Tauchi, T | 1 |
| Sugiura, I | 1 |
| Koh, K | 1 |
| Benchekroun, S; Bouchoutrouch, N; Dehbi, H; El Amrani, M; El Hadi, H; Kottwitz, D; Moumen, A; Nadifi, S; Quessar, A; Sefrioui, H | 1 |
| Biondi, A; Leoni, V | 1 |
| Cayuela, JM; Cluzeau, T; Dombret, H; Lippert, E; Maarek, O; Migeon, M; Noguera, ME; Rea, D | 1 |
| Cho, EH; Jeon, SY; Kim, HS; Kim, JA; Kwak, JY; Lee, B; Lee, NR; Song, EK; Yhim, HY; Yim, CY | 1 |
| Raanani, P | 1 |
| Bleckmann, K; Schrappe, M | 1 |
| Bartley, PA; Branford, S; Budgen, B; Hughes, E; Hughes, TP; Latham, S; Morley, AA; Ross, DM; White, D | 1 |
| Chilton, L; Cummins, M; Elliott, A; Goulden, N; Harrison, CJ; Moorman, AV; Moppett, J; Murray, J; Parker, CA; Richardson, S; Ryan, SL; Saha, V; Schwab, C; Tunstall, O; Vora, A; Wragg, C | 1 |
| Chen, Z; Li, J; Su, K; Zhang, H | 1 |
| Chang, MH; Choi, MY; Choi, SY; Do, YR; Kim, DW; Kim, DY; Kim, H; Kim, HJ; Kim, JA; Kim, SH; Kwak, JY; Kwon, JH; Lee, SE; Lee, WS; Mun, YC; Oh, S; Park, J; Park, JS; Song, HY; Zang, DY | 1 |
| Ame, S; Bennaceur-Griscelli, A; Bonnet, ML; Bourhis, JH; Chomel, JC; Guerci-Bresler, A; Legros, L; Marfaing-Koka, A; Rea, D; Rousselot, P; Sloma, I; Sorel, N; Turhan, AG | 1 |
| Angelucci, E; Audisio, E; Bassan, R; Borlenghi, E; Boschini, C; Cattaneo, C; Cavattoni, IM; Ciceri, F; Cortelezzi, A; Gianni, F; Grassi, A; Intermesoli, T; Lussana, F; Mannelli, F; Masciulli, A; Mattei, D; Oldani, E; Parolini, M; Raimondi, R; Rambaldi, A; Romani, C; Scattolin, AM; Spinelli, O; Terruzzi, E; Tosi, M | 1 |
| Califano, C; Chiaretti, S; De Fabritiis, P; Dore, F; Elia, L; Falini, B; Fanin, R; Fazi, P; Ferrara, F; Foà, R; La Nasa, G; Luppi, M; Mandelli, F; Meloni, G; Piciocchi, A; Ronco, F; Tedeschi, A; Vignetti, M; Vitale, A | 1 |
| Brower, V | 1 |
| Carré, M; Charbonnier, A; Dubruille, V; Etienne, G; Gardembas, M; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Ianotto, JC; Legros, L; Mahon, FX; Nicolini, F; Noel, MP; Rea, D; Rigal-Huguet, F; Rousselot, P; Tulliez, M; Varet, B; Villemagne, B | 1 |
| Hughes, TP; Ross, DM | 1 |
| Chang, Y; Chen, SS; Huang, XJ; Jiang, H; Jiang, Q; Li, JL; Li, LD; Liu, YR; Qin, YZ; Ruan, GR; Zhang, Y; Zhu, HH | 1 |
| Cross, NC; Erben, P; Fabarius, A; Grimwade, D; Haferlach, C; Hehlmann, R; Hochhaus, A; Metzgeroth, G; Popp, H; Reiter, A; Schmitt-Graeff, A; Schnittger, S; Walz, C | 1 |
| Akiyama, H; Jinnai, I; Kimura, Y; Maruta, A; Matsuo, K; Miyawaki, S; Miyazaki, Y; Naoe, T; Narimatsu, H; Nishii, K; Ohno, R; Ohtake, S; Sugiura, I; Takeuchi, J; Takeuchi, M; Ueda, Y; Usui, N; Yagasaki, F; Yanada, M; Yujiri, T | 1 |
| Abe, A; Hayakawa, F; Jamieson, CHM; Katsumi, A; Kitamura, K; Kiyoi, H; Minami, Y; Murata, M; Naoe, T; Nomura, Y; Wang, JYJ | 1 |
| Alimena, G; Breccia, M; Cannella, L; De Cuia, R; Diverio, D; Santopietro, M; Stefanizzi, C | 1 |
| Chung, NG; Kim, CC; Kim, HJ; Kim, YJ; Lee, DG; Lee, JW; Lee, S; Lim, J; Min, CK; Min, WS | 1 |
| Andersen, BL; Braendstrup, K; Hokland, P; Mikkelsen, LS; Nyvold, CG; Ommen, HB; Ostergaard, M; Stentoft, J | 1 |
| Gruber, F; Mustjoki, S; Porkka, K | 1 |
| Cortes, J; Jabbour, E; Jones, D; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J | 1 |
| Chang, I; Choi, D; Kim, KM; Lee, JY; Lee, WJ; Sohn, TS; Yoo, EY | 1 |
| Campiotti, L; Lo Curto, F; Mattarucchi, E; Pasquali, F; Porta, G; Rambaldi, A; Spinelli, O | 1 |
| Chen, F; Hou, M; Ji, C; Li, L; Ma, D; Sun, J; Yan, S; Zhang, M | 1 |
| Czyz, A; Komarnicki, M; Kroll, R; Lewandowski, K | 1 |
| Goldman, JM | 1 |
| Ottmann, OG; Pfeifer, H | 1 |
| Biedrzycki, B; Chia, C; Garrett-Mayer, E; Gocke, C; Harding, TC; Hege, K; Jones, R; Kasamon, YL; Kowalski, J; Levitsky, HI; Miller, CB; Murphy, K; Qin, L; Smith, BD; Tsai, HL; Tu, GH | 1 |
| Aizawa, Y; Furukawa, T; Fuse, I; Kaji, M; Masuko, M; Nakamura, T; Narita, M; Saitoh, A; Takahashi, M; Toba, K; Tochiki, N; Watanabe, N; Yamahira, A | 1 |
| Borojevic, R; Costa, ES; Dutra, FF; Freitas, MS; Guerra, MC; Maia, SF; Oliveira, GA; Otazu, IB; Silva, JL; Tabernero, MD | 1 |
| Akbulak, R; Atanackovic, D; Bartels, BM; Bartels, K; Bokemeyer, C; Brümmendorf, TH; Cao, Y; Gontarewicz, A; Gordic, M; Hildebrandt, Y; Kobold, S; Kröger, N; Lajmi, N; Luetkens, T; Meyer, S; Schafhausen, P; Stasche, T; Uhlich, F | 1 |
| Oehler, VG; Radich, JP | 2 |
| Apperley, JF; Cross, NC; Melo, JV; Score, J; Sobrinho-Simões, M; Wilczek, V | 1 |
| Bartley, PA; Branford, S; Budgen, B; Hughes, TP; Latham, S; Martin-Harris, MH; Morley, AA; Ross, DM; Wilczek, V | 1 |
| Press, RD | 1 |
| Hosen, N; Kawakami, M; Kawase, I; Morita, S; Murao, A; Nakajima, H; Narita, M; Nishida, S; Oji, Y; Oka, Y; Sakamoto, J; Shirakata, T; Sugiyama, H; Takahashi, K; Takahashi, M; Tanaka, T; Tsuboi, A | 1 |
| Harigae, H; Kato, C; Kodera, Y; Miyamura, K; Nakao, S; Nishiwaki, S; Ohashi, K; Sakamaki, H; Terakura, S | 1 |
| Heinrich, MC | 1 |
| Adenis, A; Bertucci, F; Blay, JY; Bui, BN; Chabaud, S; Chevreau, C; Cioffi, A; Cupissol, D; Duffaud, F; Emile, JF; Le Cesne, A; Pérol, D; Ray-Coquard, I; Rios, M | 1 |
| Cortes, J; Garcia-Manero, G; Hiteshew, J; Jones, D; Kantarjian, H; Koller, C; O'Brien, S; Quintás-Cardama, A; Ravandi, F; Shan, J; Verstovsek, S | 1 |
| Annunziata, M; Breccia, M; Camera, A; Cavazzini, F; Gozzini, A; Isidori, A; Montefusco, E; Morra, E; Piccaluga, PP; Pregno, P; Santini, V; Specchia, G; Stagno, F; Usala, E; Visani, G | 1 |
| Smith, BD | 1 |
| Lee, HJ; Thompson, JE; Wang, ES; Wetzler, M | 1 |
| Aranguren, PN; Bengió, R; Fernandez, I; García, J; Giere, I; Labanca, V; Lastiri, F; Lombardi, V; Magariños, AE; Martinez, L; Milone, J; Moiraghi, B; Murro, H; Pavlovsky, C; Pavlovsky, MA; Pavlovsky, S; Reinoso, FG; Uriarte, R | 1 |
| Chan, KW; Lockhart, S; McDonald, L; Rytting, M | 1 |
| Bhatia, R; Chakraborty, S; Chu, S; Huang, Q; Lin, A; McDonald, T; Snyder, DS | 1 |
| Kobayashi, K; Kobayashi, R; Mikawa, M; Morioka, K; Suzuki, D; Yamamoto, H; Yasuda, K | 1 |
| Hochhaus, A | 1 |
| Higa, B; Thakral, B; Velankar, MM; Venkataraman, G | 1 |
| Cariou, ME; Cayuela, JM; Coude, MM; Dombret, H; Luycx, O; Maarek, O; Rea, D | 1 |
| Abe, A; Hiraga, J; Inagaki, Y; Kitamura, K; Minami, M; Minami, Y; Miyamura, K; Mizuno, S; Naoe, T; Sawa, M; Ymamoto, K | 1 |
| Kantarjian, H; Liu-Dumlao, T; O'Brien, S; Ravandi, F; Thomas, DA | 1 |
| Chen, H; Chen, YH; Han, W; Huang, XJ; Liu, DH; Liu, KY; Liu, YR; Qin, YZ; Wang, Y; Xu, LP; Zhang, XH; Zhang, YY; Zhao, XY | 1 |
| Cho, BS; Chung, NG; Eom, KS; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Aricò, M; Biondi, A; Campbell, M; Castor, A; De Lorenzo, P; Escherich, G; Gandemer, V; Li, CK; Lucchini, G; Pieters, R; Röttgers, S; Saha, V; Schrappe, M; Stary, J; Valsecchi, MG; Vora, A | 1 |
| Beelen, D; Bethge, W; Bornhäuser, M; Brück, P; Burmeister, T; Dengler, J; Dreger, P; Faul, C; Gökbuget, N; Gramatzki, M; Hoelzer, D; Horst, HA; Kiani, A; Kubuschok, B; Lange, E; Ottmann, OG; Pfeifer, H; Schäfer-Eckart, K; Schwerdtfeger, R; Serve, H; Stadler, M; Stelljes, M; Vucinic, V; Wassmann, B | 1 |
| Berger, U; Gschaidmeier, H; Hehlmann, R; Hochhaus, A; Kreil, S; Kuhn, C; Lahaye, T; Merx, K; Müller, MC; Paschka, P; Schoch, C; Weisser, A | 1 |
| Atta, J; Bruck, P; Gehrke, B; Gschaidmeier, H; Hoelzer, D; Ottmann, OG; Petershofen, EK; Pfeifer, H; Scheuring, UJ; Wassmann, B | 1 |
| Arlinghaus, R; Bochinski, K; Cortes, JE; Faderl, S; Garcia-Manero, G; Giles, F; Jeha, S; Kantarjian, HM; Letvak, L; O'Brien, S; Rios, MB; Talpaz, M; Thomas, D | 1 |
| Gökbuget, N; Hoelzer, D; Ottmann, OG | 1 |
| Andersson, PO; Brune, M; Gustavsson, B; Stockelberg, D; Wadenvik, H; Wernstedt, P | 1 |
| Agis, H; Geissler, K; Sagaster, V | 1 |
| Ottmann, OG; Wassmann, B | 2 |
| Braziel, RM; Druker, BJ; Gatter, KM; Lawce, H; Loriaux, M; Magenis, RE; Mauro, MJ; Maziarz, RT; O'Dwyer, ME; Olson, SB | 1 |
| O'Dwyer, M | 1 |
| Carella, AM | 1 |
| Cervantes, F; Drummond, M; Goldman, J; Kaeda, J; Lin, F; O'Brien, S | 1 |
| Berger, U; Gschaidmeier, H; Hehlmann, R; Hochhaus, A; König, H; Kreil, S; Lahaye, T; Merx, K; Müller, MC; Paschka, P; Petzold, A; Schoch, C; Weisser, A | 1 |
| Brück, P; Gehrke, B; Gschaidmeier, H; Hoelzer, D; Ottmann, OG; Petershofen, EK; Pfeifer, H; Scheuring, UJ; Wassmann, B | 1 |
| Hwang, JY; Kim, CC; Kim, DW; Kim, HJ; Kim, YJ; Kim, YL; Lee, JW; Lee, S; Min, WS; Park, YH | 1 |
| Fujisawa, S; Hatsumi, N; Kishi, K; Miyakoshi, S; Miyawaki, S; Mori, S; Nakajima, H; Oki, M; Sakamaki, H; Sakura, T; Tanaka, Y; Ueyama, J; Yokota, A | 1 |
| Binckebanck, A; Gökbuget, N; Gschaidmeier, H; Hoelzer, D; Ottmann, OG; Reutzel, R; Scheuring, UJ; Wassmann, B | 1 |
| Fukutsuka, K; Hayashi, T; Kishimori, C; Miyanishi, S; Okumura, A; Umeki, K | 1 |
| Chung, NG; Hwang, JY; Kim, CC; Kim, DW; Kim, YJ; Kim, YL; Lee, S; Min, CK | 1 |
| Crossman, LC; O'Brien, S | 1 |
| Ueda, T | 1 |
| Hochhaus, A; Merx, K; Paschka, P | 1 |
| Hochhaus, A; La Rosée, P | 1 |
| Jinnai, I; Kawai, Y; Matsuo, K; Miyawaki, S; Naoe, T; Ohno, R; Ohtake, S; Sugiura, I; Takeuchi, J; Takeuchi, M; Towatari, M; Usui, N; Yagasaki, F; Yanada, M | 1 |
| Bhatia, R; Chu, S; Forman, SJ; Sawyers, CL; Shah, NP; Snyder, DS; Xu, H | 1 |
| Bruzzone, R; Frassoni, F; Fugazza, G; Gatti, AM; Gobbi, M; Grasso, R; Miglino, M; Quintino, S; Sessarego, M | 1 |
| Goh, HG; Kim, CC; Kim, DW; Kim, HJ; Kim, SH; Kim, TG; Kim, YJ; Kim, YL; Lee, JW; Lee, JY; Lee, S; Min, CK; Min, WS | 1 |
| Elrick, LJ; Holyoake, TL; Jorgensen, HG; Mountford, JC | 1 |
| Goldman, J | 1 |
| Eom, KS; Kim, CC; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Andreasson, C; Apperley, JF; Bua, M; Dazzi, F; Fleming, A; Goldman, JM; Howard, J; Kaeda, J; Kanfer, E; Marin, D; Olavarria, E; Rahemtulla, A; Saunders, S; Szydlo, R | 1 |
| Deininger, MW; Holyoake, TL | 1 |
| Mauro, MJ | 1 |
| Cortes, J; Dewald, GW; Kantarjian, HM; Litzow, ML; Mauro, MJ; Talpaz, M; Tefferi, A | 1 |
| Andreasson, C; Apperley, JF; Bua, M; Goldman, JM; Kaeda, JS; Marin, D; Olavarria, E; Saunders, SM | 1 |
| Antoch, G; Bauer, S; de Wit, M; Ebeling, P; Erhard, J; Flasshove, M; Grabellus, F; Hartmann, JT; Lang, H; Niebel, W; Schütte, J; Seeber, S; Taeger, G; Zeth, M | 1 |
| Lovas, N; Poros, A | 1 |
| Caplan, SN; Fetni, R; Johnson, NA | 1 |
| Asou, N; Kawakita, T; Matsuno, N; Mitsuya, H; Nanri, T | 1 |
| Cho, GJ; Chung, JS; Shin, HJ | 1 |
| Azzara', A; Carulli, G; Fazzi, R; Galimberti, S; Orciuolo, E; Petrini, M; Testi, C | 1 |
| Champlin, RE; Kantarjian, H | 1 |
| Gotoh, A; Itoh, Y; Kimura, Y; Miyazawa, K; Ohyashiki, JH; Ohyashiki, K; Sashida, G; Shoji, N; Sumi, M; Tauchi, T | 1 |
| Cortes, J | 1 |
| Deininger, MW; Mauro, MJ | 1 |
| Dziewirski, W; Grzesiakowska, U; Krawczyk, M; Nasierowska-Guttmejer, A; Nowecki, Z; Nyckowski, P; Ruka, W; Rutkowski, P | 1 |
| Amabile, M; Baccarani, M; Bassan, R; Bassi, S; Breccia, M; Cilloni, D; Frassoni, F; Iacobucci, I; Izzo, B; Lauria, F; Martinelli, G; Merante, S; Montefusco, E; Pane, F; Paolini, S; Poerio, A; Rosti, G; Saglio, G; Soverini, S; Testoni, N | 1 |
| Giles, FJ | 1 |
| Franceschino, A; Gambacorti Passerini, C; Piazza, R; Pogliani, E; Tornaghi, L | 1 |
| Calabrese, G; Di Gianfilippo, R; Di Lorenzo, R; Fantasia, D; Palka, G; Stuppia, L | 1 |
| Cesarman, E; Chen, Q; Knowles, DM; Lee, JW; Wang, YL | 1 |
| Asakura, H; Miyamura, K; Murayama, T; Nagai, K; Nakao, S; Shibayama, M; Shimadoi, S; Sugimori, C; Takami, A; Takemoto, K; Yoshida, T | 1 |
| Baccarani, M; Cilloni, D; Iacobucci, I; Martinelli, G; Pane, F; Saglio, G; Soverini, S | 1 |
| Buzyn, A; Cayuela, JM; Chalandon, Y; de Labarthe, A; Delabesse, E; Dombret, H; Escoffre, M; Huguet-Rigal, F; Ifrah, N; Lhéritier, V; MacIntyre, E; Maury, S; Pigneux, A; Réa, D; Reman, O; Rousselot, P; Thomas, X; Vekemans, MC; Vernant, JP; Witz, F | 1 |
| Jinnai, I | 1 |
| Bunjes, D; Döhner, H; Döhner, K; Greiner, J; Harsdorf, Sv; Marx, M; Ringhoffer, M; Schmitt, M; Stilgenbauer, S; Wiesneth, M; Zenz, T | 1 |
| Argilagos, RF; Dalton, WS; Hazlehurst, LA | 1 |
| Cortes, J; Giles, F; Jabbour, E; Kantarjian, H; O'Brien, S; Rios, MB | 1 |
| Casali, PG; Coco, P; Fiore, M; Gronchi, A; Lagonigro, MS; Messina, A; Miselli, F; Pilotti, S | 1 |
| Angelucci, E; Barbui, T; Bassan, R; Fabris, P; Grassi, A; Guerini, V; Intermesoli, T; Lambertenghi-Deliliers, G; Micò, C; Oldani, E; Peruta, B; Rambaldi, A; Rossi, G; Salvi, A; Spinelli, O; Tosi, M; Zanotti, MC | 1 |
| Aksenova, EV; Chelysheva, EIu; Domracheva, EV; Khoroshko, ND; Misiurin, AV; Turkina, AG; Zakharova, AV | 1 |
| Carella, AM; Lerma, E | 1 |
| Alimena, G; Breccia, M; Carmosino, I; De Angelis, B; Diverio, D; Izzo, B; Latagliata, R; Luciano, L; Mancini, M; Mandelli, F; Nanni, M; Pane, F; Picardi, M; Quarantelli, F; Rotoli, B | 1 |
| Agis, H; Esterbauer, H; Geissler, K; Haas, OA; Herndlhofer, S; Jäger, U; Mannhalter, C; Pirc-Danoewinata, H; Semper, H; Sillaber, C; Sperr, WR; Valent, P | 1 |
| Bermúdez, M; Calle, D; Fuster, JL; Galera, A; Llinares, ME; Ortuño, FJ | 1 |
| Ichikawa, N; Kobayashi, H; Shimizu, I; Sumi, M; Ueno, M; Yotsumoto, M | 1 |
| Debiec-Rychter, M; Dziewirski, W; Grzesiakowska, U; Michej, W; Nowecki, Z; Ruka, W; Rutkowski, P; Siedlecki, JA; Szawłowski, A | 1 |
| Ali, ZB; Ben Abid, H; ben Alaya, N; Dellagi, K; Elloumi, M; Hdeiji, S; Jeddi, R; Khlif, A; Meddeb, B; Menif, S; Zarrouki, S | 1 |
| Chang, HM; Kang, YK; Kim, BS; Kim, HC; Kim, KH; Kim, TW; Lee, JL; Ryu, MH; Sym, SJ; Yook, JH | 1 |
| Gschaidmeier, H; Hoelzer, D; Klein, SA; Martin, H; Ottmann, OG; Pfeifer, H; Scheuring, U; Wassmann, B | 1 |
| Nara, N | 1 |
27 review(s) available for imatinib mesylate and Minimal Disease, Residual
| Article | Year |
|---|---|
[Current treatment of philadelphia chromosome-positive acute lymphoblastic leukemia].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Middle Aged; Molecular Typing; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Young Adult | 2014 |
[Current treatment of pediatric acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child, Preschool; Clinical Trials as Topic; Cytarabine; Dexamethasone; Drug Discovery; Humans; Imatinib Mesylate; Induction Chemotherapy; Mercaptopurine; Methotrexate; Molecular Targeted Therapy; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines | 2014 |
Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.
Topics: Antineoplastic Agents; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors | 2016 |
Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Combined Modality Therapy; Dasatinib; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transplantation Conditioning; Treatment Outcome | 2009 |
Treatment strategies for CML.
Topics: Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2009 |
Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Bone Marrow Transplantation; Child; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Sensitivity and Specificity | 2006 |
Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation | 2011 |
[Chronic myeloid leukemia].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; DNA Mutational Analysis; Dose-Response Relationship, Drug; Genes, abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Remission Induction | 2011 |
Philadelphia-positive acute lymphoblastic leukemia: current treatment options.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Imidazoles; Neoplasm, Residual; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinolines; Stem Cell Transplantation; Thiazoles | 2012 |
Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Mas; Pyrimidines; Treatment Outcome | 2002 |
Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts.
Topics: Antineoplastic Agents; Antineoplastic Protocols; Benzamides; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Salvage Therapy | 2002 |
Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia.
Topics: Benzamides; Bone Marrow Transplantation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monitoring, Physiologic; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Pyrimidines; Recurrence | 2003 |
Clinical results with imatinib in chronic myeloid leukaemia.
Topics: Benzamides; Disease-Free Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Neoplastic Stem Cells; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2004 |
[Recent progress in diagnosis of and therapy for patients with leukemia].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cytarabine; Drug Monitoring; Fusion Proteins, bcr-abl; Gene Targeting; Genes, Wilms Tumor; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Pharmacogenetics; Piperazines; Pyrimidines; Recombinant Fusion Proteins; Therapeutic Equivalency; Tretinoin | 2004 |
Molecular surveillance of chronic myeloid leukemia patients in the imatinib era - evaluation of response and resistance.
Topics: Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Diagnostic Techniques; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Pyrimidines; Treatment Outcome | 2004 |
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytogenetics; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines | 2004 |
Punish the parent not the progeny.
Topics: Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2005 |
Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm, Residual; Piperazines; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Sensitivity and Specificity; WT1 Proteins | 2005 |
Can we afford to let sleeping dogs lie?
Topics: Benzamides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm, Residual; Piperazines; Pyrimidines | 2005 |
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cytarabine; Genes, abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Stem Cell Transplantation; Treatment Outcome | 2005 |
[The role of imatinib in the treatment of acute lymphoid leukemias].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Humans; Imatinib Mesylate; Immunotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome | 2005 |
Overcoming drug resistance in chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Cancer Vaccines; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Farnesyltranstransferase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Animal; Neoplasm, Residual; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases | 2006 |
Chronic myeloid leukemia in 2006: a perspective.
Topics: Benzamides; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines | 2006 |
Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Topics: Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Guidelines as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monitoring, Physiologic; Mutation; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2006 |
3. Imatinib therapy in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.
Topics: Benzamides; Clinical Trials as Topic; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines | 2007 |
[Molecular diagnosis in hematologic malignancies].
Topics: Antineoplastic Agents; Benzamides; Gene Expression Regulation, Leukemic; Gene Targeting; Genetic Therapy; Humans; Imatinib Mesylate; Leukemia; Molecular Diagnostic Techniques; Neoplasm, Residual; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Tretinoin | 2002 |
34 trial(s) available for imatinib mesylate and Minimal Disease, Residual
| Article | Year |
|---|---|
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Dasatinib; Female; Humans; Imatinib Mesylate; Male; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 2023 |
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
Topics: Adult; Aged; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Remission Induction; Survival Analysis; Treatment Outcome | 2019 |
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.
Topics: Adult; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Recurrence; Treatment Outcome; Withholding Treatment | 2013 |
Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; China; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Patient Selection; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Sample Size; Time Factors; Treatment Outcome | 2014 |
Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.
Topics: Adolescent; Adult; Aged; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Prognosis; Recurrence; Remission Induction; Secondary Prevention; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Young Adult | 2016 |
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
Topics: Adult; Antineoplastic Agents; Benzamides; Cytogenetics; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Neoplasm, Residual; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2008 |
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Young Adult | 2008 |
The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Benzamides; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Risk Factors; Stem Cell Transplantation; Time Factors | 2009 |
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.
Topics: Adult; Aged; Aminoquinolines; Benzamides; Cancer Vaccines; Female; Fusion Proteins, bcr-abl; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imatinib Mesylate; Imiquimod; Immunotherapy; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm, Residual; Pilot Projects; Piperazines; Pyrimidines; Tumor Burden | 2010 |
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; France; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm, Residual; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Risk Assessment; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating fact
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm, Residual; Patient Dropouts; Piperazines; Polyethylene Glycols; Pyrimidines; Recombinant Proteins | 2011 |
Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Argentina; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Treatment Outcome; Uruguay; Young Adult | 2011 |
Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.
Topics: Adolescent; Adult; Benzamides; Child; Child, Preschool; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult | 2012 |
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Incidence; Infant; Male; Neoplasm Recurrence, Local; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Risk Assessment; Stem Cell Transplantation; Survival Rate | 2012 |
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Patient Compliance; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Stem Cell Transplantation; Survival Analysis; Young Adult | 2013 |
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Marrow; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Survival Rate | 2002 |
Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Disease-Free Survival; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Remission Induction; Salvage Therapy | 2003 |
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
Topics: Adolescent; Adult; Aged; Benzamides; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; RNA, Neoplasm | 2003 |
Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Fusion Proteins, bcr-abl; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Salvage Therapy; Survival Rate; Treatment Outcome | 2003 |
Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.
Topics: Adult; Antineoplastic Agents; Benzamides; Clone Cells; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Recurrence; Remission Induction | 2004 |
Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Imatinib Mesylate; Incidence; Leukocyte Transfusion; Life Tables; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Remission Induction; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2003 |
A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chrom
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction | 2003 |
Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial.
Topics: Acute Disease; Adolescent; Adult; Benzamides; Combined Modality Therapy; Disease Progression; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Prospective Studies; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Transplantation, Homologous | 2004 |
Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Survival Analysis; Time Factors; Transplantation, Homologous; Treatment Outcome | 2004 |
Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Topics: Adult; Benzamides; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Predictive Value of Tests; Probability; Prognosis; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Salvage Therapy | 2004 |
The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Algorithms; Benzamides; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Probability; Pyrimidines; Recurrence; Remission Induction; RNA, Messenger; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2005 |
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytogenetic Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neoplasm, Residual; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm, Residual; Piperazines; Pyrimidines; Survival Analysis; Time Factors | 2005 |
Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Purging; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Transplantation, Autologous | 2005 |
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; beta 2-Microglobulin; Endpoint Determination; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Predictive Value of Tests; Prognosis; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Treatment Outcome | 2006 |
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Survival Analysis; Transplantation, Homologous | 2007 |
Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse.
Topics: Adult; Benzamides; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Depletion; Male; Middle Aged; Neoplasm, Residual; Pilot Projects; Piperazines; Pyrimidines; Recurrence; Risk; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2007 |
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Treatment Outcome | 2008 |
Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Digestive System Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Premedication; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Rate | 2008 |
95 other study(ies) available for imatinib mesylate and Minimal Disease, Residual
| Article | Year |
|---|---|
[Intensive chemotherapy with tyrosine kinase inhibitors in philadelphia-positive acute lymphoblastic leukemia].
Topics: Adolescent; Adult; Humans; Imatinib Mesylate; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Young Adult | 2021 |
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Real-Time Polymerase Chain Reaction | 2022 |
Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Dasatinib; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Remission Induction; Retrospective Studies; Transplantation, Homologous; Treatment Outcome; Young Adult | 2019 |
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission.
Topics: Adult; Aged; Aged, 80 and over; Cell Lineage; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Subsets; Male; Middle Aged; Neoplasm, Residual; Prognosis; Protein Kinase Inhibitors; Remission Induction | 2020 |
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
Topics: Adult; Animals; Apoptosis; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Female; Flow Cytometry; Gene Expression Profiling; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Knockout; Mice, Transgenic; Middle Aged; Neoplasm Transplantation; Neoplasm, Residual; Neoplasms, Experimental; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Real-Time Polymerase Chain Reaction; Tumor Stem Cell Assay | 2017 |
Patterns of care and clinical outcomes in primary oesophageal gastrointestinal stromal tumours (GIST): A retrospective study of the French Sarcoma Group (FSG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Endosonography; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; Female; Follow-Up Studies; France; Gastrointestinal Stromal Tumors; Humans; Image-Guided Biopsy; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Practice Patterns, Physicians'; Retrospective Studies; Tomography, X-Ray Computed | 2017 |
A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
Topics: Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Neoplasm, Residual; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction | 2017 |
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukem
Topics: Biomarkers, Tumor; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoglobulins; Male; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Receptors, Antigen, T-Cell; Recurrence; Survival Analysis; Treatment Outcome | 2018 |
Remission is good - relapse is bad.
Topics: Chromosomes; Humans; Imatinib Mesylate; Immunoglobulins; Neoplasm, Residual; Philadelphia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Antigen, T-Cell; Recurrence | 2018 |
Topics: Adolescent; Adult; Aged; Aged, 80 and over; DNA, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Protein Kinase Inhibitors; Young Adult | 2018 |
Real-time quantitative PCR: a reliable molecular diagnostic and follow-up tool for 'minimal residual disease' assessment in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Diagnostic Techniques; Neoplasm, Residual; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2018 |
A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Monitoring, Physiologic; Neoplasm, Residual; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Withholding Treatment; Young Adult | 2019 |
Is DNA a better assay for residual disease in chronic myeloid leukemia?
Topics: DNA; Genomics; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Polymerase Chain Reaction | 2018 |
Large amplicon droplet digital PCR for DNA-based monitoring of pediatric chronic myeloid leukaemia.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cohort Studies; Female; Genes, abl; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Polymerase Chain Reaction; Repetitive Sequences, Nucleic Acid; Young Adult | 2019 |
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Flow Cytometry; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoglobulin Heavy Chains; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Thiazoles; Vincristine; Young Adult | 2013 |
Endogenous erythroid colony formation in chronic myeloid leukemia: a recurrent finding associated with persistent minimal residual disease under imatinib.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biopsy; Bone Marrow; Case-Control Studies; Cell Proliferation; Colony-Forming Units Assay; Erythroid Cells; Female; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; STAT5 Transcription Factor; Treatment Outcome; Young Adult | 2013 |
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Dasatinib; Drug Administration Schedule; Female; Flow Cytometry; Genes, T-Cell Receptor; Humans; Imatinib Mesylate; Induction Chemotherapy; Infant; Male; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Benzamides; Cell Line; Cell Survival; Coculture Techniques; Cytokines; Drug Synergism; Feeder Cells; Female; Humans; Imatinib Mesylate; Immunoblotting; Janus Kinase 2; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice, Inbred BALB C; Mice, Nude; Neoplasm, Residual; Nuclear Proteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Pyrrolidines; RNA Interference; STAT5 Transcription Factor; Sulfonamides | 2014 |
Quantitative real-time polymerase chain reaction as an efficient molecular tool for detecting minimal residual disease in Moroccan chronic myeloid leukemia patients.
Topics: Adult; Aged; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Morocco; Neoplasm, Residual; Pathology, Molecular; Real-Time Polymerase Chain Reaction; Retrospective Studies | 2015 |
Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.
Topics: Adult; Antibodies, Bispecific; Antineoplastic Agents; Benzamides; Child; Clinical Trials as Topic; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis | 2015 |
Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapy.
Topics: Aged; Exons; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-bcr; Receptor, Platelet-Derived Growth Factor alpha | 2015 |
Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Incidence; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm, Residual; Prognosis; Protein Kinase Inhibitors; Recurrence; Retreatment; Retrospective Studies; Treatment Outcome | 2016 |
The Importance of Being Cured: A Chronic Myeloid Leukemia Perspective.
Topics: Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Protein Kinase Inhibitors | 2016 |
BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Clinical Decision-Making; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Pyrimidines; Real-Time Polymerase Chain Reaction | 2016 |
EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Chromosomes, Human, Pair 5; Combined Modality Therapy; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Infant; Male; Neoplasm, Residual; Oncogene Proteins, Fusion; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Sequence Deletion; Trans-Activators; Translocation, Genetic; Treatment Outcome; Young Adult | 2016 |
Clinico-pathological characteristics and prognostic factors of gastrointestinal stromal tumors among a Chinese population.
Topics: Aged; Antineoplastic Agents; Asian People; Biomarkers, Tumor; Chemotherapy, Adjuvant; China; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Mitotic Index; Multivariate Analysis; Neoplasm, Residual; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden; Tumor Suppressor Protein p53 | 2015 |
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Recurrence; Retreatment; Time Factors; Treatment Outcome | 2016 |
Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplastic Stem Cells; Protein Kinase Inhibitors; Remission Induction | 2016 |
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Recurrence; Remission Induction; Retreatment; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Pioglitazone with imatinib in CML may reduce residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Pioglitazone; Protein Kinase Inhibitors; Thiazolidinediones; Treatment Outcome | 2017 |
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; France; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Diagnostic Techniques; Neoplasm, Residual; Patient Selection; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Risk Factors; Time Factors; Treatment Outcome | 2017 |
How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?
Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Diagnostic Techniques; Neoplasm, Residual; Piperazines; Pyrimidines; Recurrence; Remission Induction | 2008 |
Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
Topics: Adolescent; Adult; Aged; Benzamides; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; RNA, Messenger; Transcription, Genetic | 2008 |
Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy.
Topics: Adult; Benzamides; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; RNA, Messenger; RNA, Neoplasm; Time Factors | 2008 |
Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction | 2009 |
[Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences].
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Early Detection of Cancer; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines | 2009 |
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.
Topics: Benzamides; Cause of Death; Cohort Studies; Cytogenetics; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Probability; Protein Kinase Inhibitors; Pyrimidines; Sensitivity and Specificity; Severity of Illness Index; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Residual and recurrent gastrointestinal stromal tumors with KIT mutations: findings at first follow-up CT after imatinib treatment.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Seeding; Neoplasm, Residual; Peptide Fragments; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Splenic Neoplasms; Tomography, X-Ray Computed | 2009 |
Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis.
Topics: Benzamides; DNA; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines; RNA, Messenger | 2009 |
Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment.
Topics: Adult; Benzamides; Cytogenetic Analysis; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction | 2010 |
Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Middle Aged; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Thiazoles; Transplantation, Autologous | 2010 |
Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System; Child; Combined Modality Therapy; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemic Infiltration; Mutation; Neoplasm Proteins; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Secondary Prevention; Thiazoles; Transplantation Conditioning | 2009 |
WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval.
Topics: Antineoplastic Agents; Benzamides; Cancer Vaccines; Combined Modality Therapy; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Peptide Fragments; Piperazines; Prognosis; Pyrimidines; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Vaccination; WT1 Proteins | 2011 |
Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Child; Child, Preschool; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Piperazines; Pyrimidines; Treatment Outcome | 2010 |
Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Benzamides; Decitabine; Disease-Free Survival; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Immunity, Humoral; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines | 2010 |
In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Stem Cell Transplantation; Young Adult | 2010 |
Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.
Topics: Antineoplastic Agents; Benzamides; DNA, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity | 2010 |
Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Tumor Burden | 2010 |
WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient.
Topics: Aged; Antineoplastic Agents; Benzamides; Cancer Vaccines; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; RNA, Messenger; T-Lymphocytes, Cytotoxic; Vaccines, Subunit; WT1 Proteins | 2010 |
Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Retrospective Studies; Transplantation, Homologous | 2010 |
Imatinib treatment of metastatic GIST: don't stop (believing).
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Multicenter Studies as Topic; Neoplasm, Residual; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2010 |
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Italy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction; Survival Analysis; Treatment Outcome | 2011 |
Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ ALL resolution after decitabine therapy.
Topics: Azacitidine; Benzamides; Child, Preschool; Chromosome Aberrations; Decitabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation | 2012 |
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.
Topics: Animals; Antineoplastic Agents; Benzamides; Bone Marrow; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Neoplasm Transplantation; Neoplasm, Residual; Neoplastic Stem Cells; Piperazines; Pyrimidines; Remission Induction; Substance Withdrawal Syndrome; Time Factors; Xenograft Model Antitumor Assays | 2011 |
Congenital dermatofibrosarcoma protuberans in a newborn infant with a massive back tumor: favorable effects of oral imatinib on the control of residual tumor growth.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Back; Benzamides; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Infant, Newborn; Neoplasm, Residual; Piperazines; Pyrimidines | 2011 |
Bone marrow with gelatinous transformation associated with residual disease in imatinib mesylate-treated chronic myelogenous leukaemia (CML).
Topics: Aged; Antineoplastic Agents; Benzamides; Biopsy, Needle; Bone Marrow; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Pancytopenia; Piperazines; Pyrimidines | 2012 |
Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm, Residual; Piperazines; Pyrimidines | 2012 |
Retention of CD34+ CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR-ABL inhibitors.
Topics: Aftercare; Antigens, CD34; Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Neoplastic Stem Cells; Piperazines; Prospective Studies; Pyrimidines | 2012 |
Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Young Adult | 2012 |
Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Betamethasone; Biomarkers, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Homologous; Vincristine | 2002 |
[Treatment of residual disease in chronic myeloid leukemia with STI-571 (Glivec)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines | 2002 |
Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.
Topics: Adult; Aged; Benzamides; Case-Control Studies; Chromosomes, Human, Pair 8; Clone Cells; Cytogenetic Analysis; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Trisomy | 2003 |
Current use of imatinib in the treatment of chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines; Treatment Outcome | 2003 |
Questioning the aim of CML therapy in the era of Imatinib?
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines | 2003 |
Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib.
Topics: Adult; Aged; Benzamides; Cytogenetic Analysis; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; RNA, Neoplasm | 2003 |
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Survival Rate | 2003 |
[The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
Topics: Adenosine Triphosphate; Adult; Aged; Benzamides; Binding Sites; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neoplasm, Residual; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2003 |
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
Topics: Adult; Aged; Antigens, CD34; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neoplasm, Residual; Neoplastic Stem Cells; Piperazines; Pyrimidines; Remission Induction; RNA, Messenger | 2005 |
Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Chromosome Banding; Cytogenetic Analysis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Interphase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metaphase; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Survival Rate | 2004 |
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Prognosis; Pyrimidines; Recurrence; Remission Induction; Risk Factors | 2005 |
Baseline disease risk and response to therapy in chronic myeloid leukemia: necessary predictive tools then and now.
Topics: Benzamides; Cytogenetic Analysis; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Prognosis; Pyrimidines | 2005 |
Isolated central nervous system relapse in patients with chronic myeloid leukemia on imatinib mesylate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Central Nervous System Neoplasms; Chronic Disease; Fatal Outcome; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Recurrence; Remission Induction | 2005 |
Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation.
Topics: Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 16; Exons; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm, Residual; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Recurrence; Remission Induction | 2005 |
Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: difficulties at diagnosis and rational of the therapeutic strategy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Imatinib Mesylate; Interferons; Leukemia, Hairy Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Rituximab; Treatment Outcome | 2006 |
Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Cancer Vaccines; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous | 2003 |
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Clinical Trials as Topic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Stem Cell Transplantation; Survival Rate | 2005 |
Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients.
Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Nucleic Acid Amplification Techniques; Piperazines; Pyrimidines; RNA, Neoplasm | 2005 |
Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Prognosis; Pyrimidines; Remission Induction | 2006 |
Clone wars in CML.
Topics: Alleles; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm, Residual; Piperazines; Pyrimidines | 2006 |
Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction; Treatment Failure; Treatment Outcome | 2006 |
Fluorescence in situ hybridization analysis of minimal residual disease and the relevance of the der(9) deletion in imatinib-treated patients with chronic myeloid leukemia.
Topics: Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 9; Follow-Up Studies; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines | 2006 |
beta-Glucuronidase is an optimal normalization control gene for molecular monitoring of chronic myelogenous leukemia.
Topics: Benzamides; Fusion Proteins, bcr-abl; Gene Expression; Glucuronidase; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Diagnostic Techniques; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Pyrimidines; Reference Standards; Sample Size | 2006 |
Successful treatment of minimal residual disease-positive Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib followed by reduced-intensity unrelated cord blood transplantation after allogeneic peripheral blood stem cell transplant
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Female; Humans; Imatinib Mesylate; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Transplantation, Homologous | 2006 |
Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Cell Adhesion; Drug Resistance, Neoplasm; Fibronectins; Flavonoids; Humans; Imatinib Mesylate; Integrin beta1; K562 Cells; Leukemia; Membrane Proteins; Mitogen-Activated Protein Kinases; Neoplasm, Residual; Piperazines; Proto-Oncogene Proteins; Pyrimidines; RNA Interference; RNA, Small Interfering | 2007 |
Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.
Topics: Benzamides; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Survival Analysis | 2007 |
Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Benzamides; Biomarkers, Tumor; Clinical Trials as Topic; Cohort Studies; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Gene Deletion; Gene Rearrangement, B-Lymphocyte; Gene Rearrangement, T-Lymphocyte; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Kinetics; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Multicenter Studies as Topic; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Piperazines; Polymerase Chain Reaction; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins; Pyrimidines; Remission Induction; Risk; Survival Analysis; Survival Rate; T-Cell Acute Lymphocytic Leukemia Protein 1; Translocation, Genetic; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2007 |
[Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Topics: Adult; Antineoplastic Agents; Benzamides; beta 2-Microglobulin; Biomarkers, Tumor; Bone Marrow; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity | 2007 |
Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Monitoring, Physiologic; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Histamine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monitoring, Physiologic; Neoplasm, Residual; Piperazines; Probability; Prognosis; Pyrimidines; Radioimmunoassay; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2007 |
Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Child, Preschool; Disease-Free Survival; Female; Flow Cytometry; Humans; Imatinib Mesylate; Male; Neoplasm Staging; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous | 2007 |
Successful treatment with interferon-alpha-2b and imatinib in an adult Japanese male with Philadelphia chromosome-positive acute lymphoblastic leukemia and minimal residual disease following allogeneic transplantation.
Topics: Antineoplastic Agents; Asian People; Benzamides; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recombinant Proteins; Remission Induction; Transplantation, Homologous | 2008 |
Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Computer Systems; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Tumor Burden; Tunisia | 2009 |
Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Marrow Transplantation; Colitis; Combined Modality Therapy; Enzyme Inhibitors; Female; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Immunosuppression Therapy; Interferon-alpha; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphocyte Transfusion; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neutropenia; Piperazines; Pyrimidines; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous | 2001 |